With late-phase trials advancing, novel mechanisms emerging, and global regulatory expectations evolving, the dry AMD and GA field is accelerating exponentially. Returning digitally for its sixth year, this summit is the only industry-led forum focused exclusively on the therapeutic development for dry AMD and GA.

Hear from 19+ experts across biotech, investment, and consulting, including leaders from Apellis, Ocugen, Clearside Biomedical, Annexon, and VisgenX, as well as FDA-experienced advisors and global investors - as they showcase how to navigate regulatory complexity, de-risk development decisions, and accelerate novel dry AMD and Geographic atrophy therapies toward clinical and commercial success.

Join this exclusive forum to stay ahead of the field with real-time updates on retinal clinical strategy, evolving regulatory expectations, precision ocular delivery innovation, and investment trends shaping the future of dry AMD and geographic atrophy therapeutics.

View the event here.